share_log

S-1: General form for registration of securities under the Securities Act of 1933

S-1: General form for registration of securities under the Securities Act of 1933

S-1：证券上市注册声明
美股SEC公告 ·  2024/11/16 05:21

Moomoo AI 已提取核心信息

180 Life Sciences Corp. has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on November 15, 2024, for the issuance of common stock shares. The registration statement includes a prospectus for the resale of up to 1,900,138 shares of common stock by the selling stockholder, Armistice Capital, LLC. These shares are issuable upon the exercise of warrants acquired by the selling stockholder under an inducement agreement. The company will not receive any proceeds from the sale of shares by the selling stockholder. However, if all warrants are exercised for cash, 180 Life Sciences may receive up to approximately $2,850,207, which it intends to use for operationalizing and developing its recently acquired Technology Gaming Platform, and for general corporate and legal expenses. The common stock is traded on the Nasdaq Capital Market under the symbol 'ATNF'. The company has also detailed its capital structure, including its authorized common and preferred stock, and outlined certain anti-takeover provisions in its certificate of incorporation and bylaws.
180 Life Sciences Corp. has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on November 15, 2024, for the issuance of common stock shares. The registration statement includes a prospectus for the resale of up to 1,900,138 shares of common stock by the selling stockholder, Armistice Capital, LLC. These shares are issuable upon the exercise of warrants acquired by the selling stockholder under an inducement agreement. The company will not receive any proceeds from the sale of shares by the selling stockholder. However, if all warrants are exercised for cash, 180 Life Sciences may receive up to approximately $2,850,207, which it intends to use for operationalizing and developing its recently acquired Technology Gaming Platform, and for general corporate and legal expenses. The common stock is traded on the Nasdaq Capital Market under the symbol 'ATNF'. The company has also detailed its capital structure, including its authorized common and preferred stock, and outlined certain anti-takeover provisions in its certificate of incorporation and bylaws.
180 Life Sciences 公司已于2024年11月15日向美国证券交易委员会（SEC）提交了一份注册声明，用于发行普通股股份。注册声明包括一份拟售出高达1,900,138股普通股的概要，由卖方股东Armistice Capital，LLC持有。这些股份可通过卖方股东根据诱因协议获取的认股权证行使而发行。公司不会从卖方股东出售股份中获得任何收益。但是，如果所有认股权证均以现金行使，180 Life Sciences可能最多可获得约2,850,207美元，其拟用于运营和开发其最近收购的科技游戏平台，并用于一般公司和法律费用。该普通股在纳斯达克资本市场上以“ATNF”标志交易。该公司还详细说明了其资本结构，包括其授权的普通股和优先股，并概述了其公司章程和公司规程中的某些反收购规定。
180 Life Sciences 公司已于2024年11月15日向美国证券交易委员会（SEC）提交了一份注册声明，用于发行普通股股份。注册声明包括一份拟售出高达1,900,138股普通股的概要，由卖方股东Armistice Capital，LLC持有。这些股份可通过卖方股东根据诱因协议获取的认股权证行使而发行。公司不会从卖方股东出售股份中获得任何收益。但是，如果所有认股权证均以现金行使，180 Life Sciences可能最多可获得约2,850,207美元，其拟用于运营和开发其最近收购的科技游戏平台，并用于一般公司和法律费用。该普通股在纳斯达克资本市场上以“ATNF”标志交易。该公司还详细说明了其资本结构，包括其授权的普通股和优先股，并概述了其公司章程和公司规程中的某些反收购规定。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Chimerix
    CMRX
    -- 8.420
    Radiopharm Theranostics
    RADX
    -- 7.552
    Silexion Therapeutics
    SLXN
    -- 1.395
    Celularity
    CELU
    -- 1.3000
    Plus Therapeutics
    PSTV
    -- 0.3619
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    科技巨头财报季如火如荼，英伟达压轴会表现如何？
    星期四， $亚马逊 (AMZN.US)$ 股价在公司报告第四季度调整后每股收益为1.86美元，预估为每股1.50美元，营业收入为1877.9亿，预估为1873.2亿后下跌。该公司预测第一季度的营业收入数字低于华尔街的预期，预测本季度最多为1550亿，而分析师希望为1580亿。 星 展开
    亚马逊盈利预告：猜测开盘价，获取奖励！